{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T01:58:01Z","timestamp":1789178281800,"version":"build-2803163510"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,9]]},"DOI":"10.7759\/cureus.101206","type":"journal-article","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T07:28:17Z","timestamp":1768030097000},"source":"Crossref","is-referenced-by-count":3,"title":["Hemophagocytic Lymphohistiocytosis Secondary to Immunotherapy Toxicity in a Patient With Breast Cancer: A Case Report"],"prefix":"10.7759","author":[{"given":"Abdullah","family":"Alhouri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hari","family":"Johal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricky","family":"Frazer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2018894618","article-title":"Recommendations for the management of hemophagocytic lymphohistiocytosis in adults","volume":"133","author":"La Ros\u00e9e P","year":"2019","unstructured":"La Ros\u00e9e P, Horne A, Hines M, et al.. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood. 2019, 133:2465-77. 10.1182\/blood.2018894618","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-041610-134208","article-title":"Familial and acquired hemophagocytic lymphohistiocytosis","volume":"63","author":"Janka GE","year":"2012","unstructured":"Janka GE. Familial and acquired hemophagocytic lymphohistiocytosis. Annu Rev Med. 2012, 63:233-46. 10.1146\/annurev-med-041610-134208","journal-title":"Annu Rev Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter JI","year":"2007","unstructured":"Henter JI, Horne A, Aric\u00f3 M, et al.. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007, 48:124-31. 10.1002\/pbc.21039","journal-title":"Pediatr Blood Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0598-9","article-title":"Haemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: analysis of WHO global database of individual case safety reports","volume":"7","author":"Noseda R","year":"2019","unstructured":"Noseda R, Bertoli R, M\u00fcller L, Ceschi A. Haemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: analysis of WHO global database of individual case safety reports. J Immunother Cancer. 2019, 7:117. 10.1186\/s40425-019-0598-9","journal-title":"J Immunother Cancer"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpccr.2022.100202","article-title":"Hemophagocytic lymphohistiocytosis as a complication of immune checkpoint inhibitor therapy for sarcoma","volume":"8","author":"Kenworthy C","year":"2022","unstructured":"Kenworthy C, Di M, Deshpande H. Hemophagocytic lymphohistiocytosis as a complication of immune checkpoint inhibitor therapy for sarcoma. Curr Probl Cancer Case Rep. 2022, 8:100202. 10.1016\/j.cpccr.2022.100202","journal-title":"Curr Probl Cancer Case Rep"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199005030-00002","article-title":"Immunotoxic side-effects of drug therapy","volume":"5","author":"Mitchell JA","year":"1990","unstructured":"Mitchell JA, Gillam EM, Stanley LA, Sim E. Immunotoxic side-effects of drug therapy. Drug Saf. 1990, 5:168-78. 10.2165\/00002018-199005030-00002","journal-title":"Drug Saf"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2024.102896","article-title":"Hemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitor use: a review of the current knowledge and future directions","volume":"110","author":"Walmsley CS","year":"2025","unstructured":"Walmsley CS, Schoepflin Z, De Brabandt C, Rangachari D, Berwick S, Patell R. Hemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitor use: a review of the current knowledge and future directions. Blood Cells Mol Dis. 2025, 110:102896. 10.1016\/j.bcmd.2024.102896","journal-title":"Blood Cells Mol Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s41199-020-0050-3","article-title":"Pembrolizumab-induced hemophagocytic lymphohistiocytosis: an immunotherapeutic challenge","volume":"5","author":"Kalmuk J","year":"2020","unstructured":"Kalmuk J, Puchalla J, Feng G, Giri A, Kaczmar J. Pembrolizumab-induced hemophagocytic lymphohistiocytosis: an immunotherapeutic challenge. Cancers Head Neck. 2020, 5:3. 10.1186\/s41199-020-0050-3","journal-title":"Cancers Head Neck"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-023-04625-3","article-title":"Hemophagocytic lymphohistiocytosis following pembrolizumab and bevacizumab combination therapy for cervical cancer: a case report and systematic review","volume":"24","author":"Zhai C","year":"2024","unstructured":"Zhai C, Jin X, You L, et al.. Hemophagocytic lymphohistiocytosis following pembrolizumab and bevacizumab combination therapy for cervical cancer: a case report and systematic review. BMC Geriatr. 2024, 24:32. 10.1186\/s12877-023-04625-3","journal-title":"BMC Geriatr"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1394543","article-title":"Hemophagocytic lymphohistiocytosis\/cytokine release syndrome secondary to neoadjuvant pembrolizumab for triple-negative breast cancer: a case study","volume":"14","author":"Patton L","year":"2024","unstructured":"Patton L, Monteith B, Heffernan P, Herzinger T, Wilson BE. Hemophagocytic lymphohistiocytosis\/cytokine release syndrome secondary to neoadjuvant pembrolizumab for triple-negative breast cancer: a case study. Front Oncol. 2024, 14:1394543. 10.3389\/fonc.2024.1394543","journal-title":"Front Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16630","article-title":"Haemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitors: a descriptive case study and literature review","volume":"189","author":"Dupr\u00e9 A","year":"2020","unstructured":"Dupr\u00e9 A, Michot JM, Schoeffler A, et al.. Haemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitors: a descriptive case study and literature review. Br J Haematol. 2020, 189:985-92. 10.1111\/bjh.16630","journal-title":"Br J Haematol"},{"key":"ref12","unstructured":"Management of immunotherapy-related toxicities. (2024). Accessed. 03 January, 2026: https:\/\/www.geoq.info\/pub\/documents\/IMMUNOTHERAPIE\/immunotherapie_lignes-directrices_238.pdf?utm_source=chatgpt.com."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/441608-hemophagocytic-lymphohistiocytosis-secondary-to-immunotherapy-toxicity-in-a-patient-with-breast-cancer-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T07:28:18Z","timestamp":1768030098000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/441608-hemophagocytic-lymphohistiocytosis-secondary-to-immunotherapy-toxicity-in-a-patient-with-breast-cancer-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.101206","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,9]]}}}